This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: congenital pure red cell aplasia, Diamond-Blackfan anemia (DBA), congenital hypoplastic anemia, Blackfan-Diamond syndrome
Congenital pure red cell aplasia was first described by Joseph Josephs in 1936, and subsequently, in 1938, Louis K. Diamond and Kenneth D. Blackfan systematically described and reported it as a distinct clinical syndrome. Diamond and Blackfan defined the disease as a syndrome of severe anemia arising in infancy with normal white blood cells and platelets, and reported selective loss of erythroid precursors in the bone marrow as its hallmark. The disease later came to be called Diamond-Blackfan anemia (DBA) after the two investigators.
In 1951, the Gasser and Diamond groups reported that corticosteroids (ACTH, later prednisolone) were effective for this disease. This became the foundation of treatment for congenital pure red cell aplasia. Later, however, it was recognized that not all patients respond to steroids, and that even responders sometimes have severe adverse effects.
In 1976, Alter et al. first reported hematopoietic stem cell transplantation in a patient with Diamond-Blackfan anemia. After the discovery of RPS19 mutations by Draptchinskaia et al. in 1999, DBA was revealed to be a disorder of ribosome biogenesis (ribosomopathy). Mutations in more than 20 ribosomal protein genes have since been identified, and the molecular mechanism of congenital pure red cell aplasia has largely been elucidated.
The main cause of congenital pure red cell aplasia is heterozygous loss-of-function mutations in genes encoding the proteins that make up the ribosomal subunits. Various types are identified, including large deletions (50%), missense mutations, nonsense mutations, and splice-site mutations. RPS19 (about 25%) is the most common, followed by RPL5 (about 9%), RPL11 (about 7%), RPL35A (about 3%), RPS26 (about 3%), and RPS24 (about 2%).
| Gene | Subunit | Frequency (%) | Associated malformations |
|---|---|---|---|
| RPS19 | 40S | About 25% | Diverse clinical phenotypes |
| RPL5 | 60S | About 9% | High frequency of thumb malformations, cleft palate, and cardiac malformations |
| RPL11 | 60S | About 7% | High frequency of thumb malformations |
| RPS26 | 40S | About 3% | Tendency toward anemia alone without malformations |
| GATA1 (X-linked) | - | Rare | X-linked inheritance; may be accompanied by platelet abnormalities |
Some DBA-like syndromes can be caused by mutations in the GATA1 gene (X-linked). TSR2 gene mutations also cause a DBA-like phenotype and follow an X-linked inheritance pattern. In about 35–40% of all DBA patients, no causative gene mutation is identified with current molecular genetic testing.
About 45% of congenital pure red cell aplasia cases are inherited with a family history, mostly following an autosomal dominant inheritance pattern. About 55% overall are de novo mutations with no family history. Cases due to GATA1 or TSR2 mutations show X-linked recessive inheritance.
With heterozygous deletion of a ribosomal subunit protein, excess free ribosomal proteins (RPL5, RPL11) bind to MDM2 and stabilize p53, causing cell-cycle arrest and apoptosis via the p53-p21 pathway. The reason activation of this pathway acts selectively on erythroid precursors is that GATA1 protein expression is translation-dependent, making it especially vulnerable when ribosome function is reduced.
Patients with RPL5 and RPL11 mutations have a higher frequency of associated congenital malformations (especially thumb malformations, cleft palate, and cardiac malformations). Patients with RPS26 mutations tend to have anemia alone without malformations.
Congenital pure red cell aplasia is a rare disease occurring in about 5–7 per 1 million births. There is no or only a slight sex difference, and it occurs in all ethnic groups. About 35% present at birth or in the neonatal period, and more than 90% of diagnoses are made within the first year of life.
In Korea, it is registered as a rare disease, and dozens of new diagnoses are reported annually. DBA patient cohorts have been established, centered on pediatric hematology-oncology departments, and outcomes of hematopoietic stem cell transplantation continue to improve.
The Diamond-Blackfan Anemia Registry (DBAR, USA), EWOG-DBA (Europe), and the Japanese DBA study group, among others, are collecting data, and through these registries the long-term clinical course, treatment response, and frequency of complications are being systematically analyzed.
When heterozygous mutations in ribosomal protein genes reduce only one of the large ribosomal subunit (60S) or small ribosomal subunit (40S) proteins, an imbalance in ribosomal subunit assembly (ribosomal imbalance) occurs. Surplus free ribosomal proteins (especially RPL5, RPL11) bind directly to MDM2, the p53 inhibitor, blocking MDM2-mediated ubiquitination and degradation of p53.
Activated p53 transcriptionally activates cell-cycle regulatory genes such as CDKN1A (p21), causing G1 cell-cycle arrest. At the same time, it induces transcription of pro-apoptotic genes such as PUMA and BAX, initiating mitochondrial-pathway apoptosis. The reason this process is concentrated in erythroid precursors (BFU-E, CFU-E, proerythroblasts) is that GATA1 expression is translation-dependent.
Because of its strong 5' UTR structure, GATA1 mRNA has low translation efficiency, so sufficient GATA1 protein is produced only when ribosome function is adequate. When GATA1 protein decreases due to reduced ribosome function, transcriptional activation of genes promoting erythroid differentiation (EPOR, ALAS2, HBA, HBB, etc.) declines, impairing the differentiation and survival of erythroid precursors.
The main symptoms are those caused by severe anemia. Within weeks to months after birth, extreme pallor, feeding difficulty, hyperpnea, and tachycardia appear. In severe cases, congestive heart failure, hepatomegaly, and cyanosis occur. Growth retardation may accompany these.
Congenital malformations are present in about 30–47% of patients. The most specific malformations are thumb abnormalities (triphalangeal thumb, duplicated thumb, hypoplastic or absent thumb). Cleft lip and palate, brachycephaly, microphthalmia, cataracts, strabismus, congenital heart malformations, renal malformations, and genitourinary malformations are also reported.
In patients receiving long-term steroid therapy, growth impairment, adrenocortical insufficiency, Cushing syndrome, and osteoporosis appear. In chronically transfused patients, endocrine abnormalities due to iron overload occur. DBA patients have an increased risk of AML, MDS, osteosarcoma, head and neck cancer, and colon cancer, among others.
Severe pallor is the most prominent sign. Splenomegaly is typically absent or mild, which helps differentiate it from hemolytic anemia. Thumb malformations, a characteristic facial appearance, and short stature may be observed. In patients on long-term steroid therapy, cushingoid facies, abdominal obesity, and growth impairment appear.
The complete blood count is characterized by normocytic or macrocytic normochromic anemia (Hb 3–8 g/dL), markedly decreased reticulocytes (0–1%), and normal white blood cell and platelet counts. The HbF proportion remains high for age. Erythrocyte adenosine deaminase (eADA) activity is increased in about 80–90% of patients.
Bone marrow aspiration is characterized by normal cellularity together with a marked reduction or absence of erythroid precursors. Myeloid and megakaryocytic lineage cells are normal. In some cases, very few proerythroblasts remain.
Increased erythrocyte adenosine deaminase (eADA) activity is a useful tool for DBA screening. Increased eADA (1.5–2 times normal or higher) is found with high sensitivity in DBA and is normal in anemias of other causes such as iron deficiency anemia and TEC. Because it can be performed as a simple blood test, it is suitable for first-line screening.
Blood tests must be performed in infants with congenital malformations (especially thumb abnormalities). In families of DBA patients, hematologic screening and eADA measurement of parents and siblings are recommended. Family screening is important for donor selection, genetic counseling, and identification of carriers.
Diagnostic criteria: (1) normocytic or macrocytic anemia presenting before 1 year of age, (2) reticulocytopenia, (3) decreased erythroid precursors in the bone marrow, (4) normal white blood cells and platelets. If all of these criteria are met, classic DBA is diagnosed. If a gene mutation is identified by molecular genetic testing or there is a family history, the diagnosis can be made even if some criteria are not met.
The causative mutation is identified with a ribosomal protein gene panel (RPS19, RPL5, RPL11, RPL35A, RPS24, RPS17, RPS26, RPL15, RPL27, etc.) or WES. GATA1 and TSR2 are also included in the panel. If the panel is negative, MLPA is used to search for large deletions.
Transient erythroblastopenia of childhood (TEC) is differentiated by spontaneous recovery after age 2 and normal eADA. Fanconi anemia is differentiated by pancytopenia and DEB/MMC testing. Pearson syndrome is differentiated by mitochondrial DNA deletion.
Prednisolone is started at 2 mg/kg/day and, after a treatment response, tapered to the minimum effective dose (including alternate-day dosing). The response rate is 70–80%. Minimizing long-term adverse effects (growth impairment, Cushing syndrome, osteoporosis, infection) is a treatment goal.
In patients who are steroid-refractory or have adverse effects, regular transfusion every 4–6 weeks (maintaining Hb > 8 g/dL) is standard. Irradiated, leukoreduced, CMV-negative blood products are recommended. Iron overload is prevented with iron chelation (deferasirox, deferoxamine).
HSCT is the only curative treatment. It is actively considered in cases of steroid refractoriness, transfusion dependence, or severe adverse effects, and when an HLA-matched donor is identified. Transplantation before age 9 has better outcomes. The 5-year survival rate of HLA-matched sibling HSCT is 80–90%. Luspatercept showed an effect of reducing transfusion dependence in some patients in a clinical trial in adult DBA patients.
Patients with a sustained response to steroids (about 40% of all patients) have a relatively favorable prognosis. With spontaneous remission (about 20%) after a steroid response, blood counts normalize without treatment. The long-term survival rate after HLA-matched sibling HSCT is 80–90%. In the transfusion-dependent group, iron overload complications are the main problem.
In DBA patients, the cumulative risk of AML, MDS, osteosarcoma, head and neck cancer, colon cancer, and others is about 5 or more times higher than in the general population. The cumulative cancer incidence by age 40 is reported to be about 20%. With appropriate management, survival into adulthood is possible, but continuous specialized follow-up is required.
Because inheritance is autosomal dominant, screening tests and genetic counseling are needed for the patient's parents and siblings. After the causative mutation is identified, prenatal genetic testing by CVS or amniocentesis is possible. With PGT-M, implantation of affected embryos can be prevented and HLA-matched savior siblings can be selected.
During steroid therapy, calcium/vitamin D supplementation, vaccination, and growth monitoring. In transfused patients, iron overload monitoring with regular serum ferritin, liver MRI T2*, and cardiac MRI T2*. Annual hematologic follow-up testing and regular screening for early detection of malignancies are recommended.